SML0517
Amlexanox
≥98% (HPLC)
别名:
2-Amino-7-(1-methylethyl)-5-oxo-5H-[1]Benzopyrano[2,3-b]pyridine-3-carboxylic acid, AA 673, Amoxanox, CHX 3673
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C16H14N2O4
化学文摘社编号:
分子量:
298.29
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
InChI key
SGRYPYWGNKJSDL-UHFFFAOYSA-N
SMILES string
CC(C)c1ccc2Oc3nc(N)c(cc3C(=O)c2c1)C(O)=O
InChI
1S/C16H14N2O4/c1-7(2)8-3-4-12-9(5-8)13(19)10-6-11(16(20)21)14(17)18-15(10)22-12/h3-7H,1-2H3,(H2,17,18)(H,20,21)
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 10 mg/mL at warmed, clear
shipped in
wet ice
storage temp.
−20°C
Quality Level
Gene Information
human ... PDE4A(5141), PDE4B(5142), PDE4C(5143), PDE4D(5144)
正在寻找类似产品? 访问 产品对比指南
General description
Amlexanox is an anti-allergic drug with anti-inflammatory properties.
Biochem/physiol Actions
Amlexanox elevates the amount of nonsense-containing mRNAs in treated cells and helps to generate full-length proteins effectively.
Amlexanox is an anti-allergy and anti-asthma drug that blocks histamine and leukotriene release from leukocytes and mast cells. Amlexanox has also been shown to inhibit cahaperone activity of Hsp90, and S100A13, which is involved in transport of proteins devoid of signal peptide sequences.
Amlexanox is an anti-allergy, anti-ulcer drug; S100A13 inhibitor.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Sandhya G Rani et al.
Biochemistry, 49(11), 2585-2592 (2010-02-25)
S100A13 and acidic fibroblast growth factor (FGF1) are involved in a wide array of important biological processes, such as angiogenesis, cell differentiation, neurogenesis, and tumor growth. Generally, the biological function of FGF1 is to recognize a specific tyrosine kinase on
Nesrine Benslimane et al.
Pharmaceuticals (Basel, Switzerland), 16(7) (2023-07-29)
Nonsense mutations are involved in multiple peripheral neuropathies. These mutations induce the presence of a premature termination codon (PTC) at the mRNA level. As a result, a dysfunctional or truncated protein is synthesized, or even absent linked to nonsense-mediated mRNA
Brenda Murray et al.
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 34(7), 413-419 (2005-07-14)
Recurrent minor aphthous ulceration (RAU) is a common condition which is multifactorial in origin. This study, firstly, aimed to treat the prodromal stage of RAU with Aphtheal (5% amlexanox paste) to determine if ulcer development could be prevented. A second
Jie Liu et al.
Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 102(4), 475-481 (2006-09-26)
The objectives of this study were to clinically determine the topical efficacy and safety of amlexanox oral adhesive tablets in the treatment of recurrent minor aphthous ulcerations (MiRAU) in a Chinese cohort. A randomized, double-blind, vehicle-controlled, unparallel multicenter clinical trial
B Murray et al.
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 35(2), 117-122 (2006-01-25)
The study was designed to determine the efficacy of OraDisc (active component 2 mg amlexanox) on the prevention of aphthous ulcers treated at the prodromal stage. Thermographic imaging was used to confirm the presence of a prodromal ulcer. Fifty-two patients
商品
Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持